Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma

Arch Dermatol. 2009 Sep;145(9):985-8. doi: 10.1001/archdermatol.2009.229.

Authors

Jennifer M Gardner¹, Katherine G Evans, Steven Goldstein, Ellen J Kim, Carmela C Vittorio, Alain H Rook

Affiliation

¹ Department of Dermatology, University of Pennsylvania, 3600 Spruce St, 2 Maloney Bldg, Philadelphia, PA 19104, USA. jennifer.gardner@uphs.upenn.edu

PMID: 19770436
DOI: 10.1001/archdermatol.2009.229

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Anti-Idiotypic / analysis
Antibodies, Anti-Idiotypic / immunology
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / therapeutic use*
Diagnosis, Differential
Dose-Response Relationship, Drug
Female
Fluorescent Antibody Technique, Indirect
Follow-Up Studies
Histone Deacetylase Inhibitors
Humans
Hydroxamic Acids / administration & dosage
Hydroxamic Acids / therapeutic use*
Immunoglobulin G / immunology
Lymphoma, T-Cell, Cutaneous / complications
Lymphoma, T-Cell, Cutaneous / diagnosis
Lymphoma, T-Cell, Cutaneous / drug therapy*
Middle Aged
Pemphigoid, Bullous / complications
Pemphigoid, Bullous / drug therapy*
Pemphigoid, Bullous / pathology
Skin Neoplasms / complications
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology
Vorinostat

Substances

Antibodies, Anti-Idiotypic
Antineoplastic Agents
Histone Deacetylase Inhibitors
Hydroxamic Acids
Immunoglobulin G
Vorinostat